Caspofungin resistance in clinical Aspergillus flavus isolates
Copyright © 2021 SFMM. Published by Elsevier Masson SAS. All rights reserved..
INTRODUCTION AND AIMS: The present study was conducted to determine the candidate genes involved in caspofungin (CAS) resistance in clinical isolates of Aspergillus flavus (A. flavus).
MATERIALS AND METHODS: The antifungal susceptibility assay of the CAS was performed on 14 clinical isolates of A. flavus using the CLSI-M-38-A2 broth micro-dilution protocol. Since CAS had various potencies, the minimum effective concentration (MEC) of anidulafungin (AND) was also evaluated in the present study. The FKS1 gene sequencing was conducted to assess whether mutations occurred in the whole FKS1 gene as well as hot spot regions of the FKS1 gene of the two resistant isolates. A complementary DNA-amplified fragment length polymorphism (CDNA-AFLP) method was performed to investigate differential gene expression between the two resistant and two sensitive clinical isolates in the presence of CAS. Furthermore, quantitative real-time PCR (QRT-PCR) was utilized to determine the relative expression levels of the identified genes.
RESULTS: No mutations were observed in the whole FKS1 gene hot spot regions of the FKS1 genes in the resistant isolates. A subset of two genes with known biological functions and four genes with unknown biological functions were identified in the CAS-resistant isolates using the CDNA-AFLP. The QRT-PCR revealed the down-regulation of the P-type ATPase and ubiquinone biosynthesis methyltransferase COQ5 in the CAS-resistant isolates, compared to the susceptible isolates.
CONCLUSION: The findings showed that P-type ATPase and ubiquinone biosynthesis methyltransferase COQ5 might be involved in the CAS-resistance A. flavus clinical isolates. Moreover, a subset of genes was differentially expressed to enhance fungi survival in CAS exposure. Further studies are recommended to highlight the gene overexpression and knock-out experiments in A. flavus or surrogate organisms to confirm that these mentioned genes confer the CAS resistant A. flavus.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal de mycologie medicale - 31(2021), 4 vom: 17. Dez., Seite 101166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yassin, Zeynab [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 17.01.2022 Date Revised 17.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.mycmed.2021.101166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328385271 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328385271 | ||
| 003 | DE-627 | ||
| 005 | 20231225202828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.mycmed.2021.101166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1094.xml |
| 035 | |a (DE-627)NLM328385271 | ||
| 035 | |a (NLM)34293598 | ||
| 035 | |a (PII)S1156-5233(21)00056-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yassin, Zeynab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Caspofungin resistance in clinical Aspergillus flavus isolates |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2022 | ||
| 500 | |a Date Revised 17.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 SFMM. Published by Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION AND AIMS: The present study was conducted to determine the candidate genes involved in caspofungin (CAS) resistance in clinical isolates of Aspergillus flavus (A. flavus) | ||
| 520 | |a MATERIALS AND METHODS: The antifungal susceptibility assay of the CAS was performed on 14 clinical isolates of A. flavus using the CLSI-M-38-A2 broth micro-dilution protocol. Since CAS had various potencies, the minimum effective concentration (MEC) of anidulafungin (AND) was also evaluated in the present study. The FKS1 gene sequencing was conducted to assess whether mutations occurred in the whole FKS1 gene as well as hot spot regions of the FKS1 gene of the two resistant isolates. A complementary DNA-amplified fragment length polymorphism (CDNA-AFLP) method was performed to investigate differential gene expression between the two resistant and two sensitive clinical isolates in the presence of CAS. Furthermore, quantitative real-time PCR (QRT-PCR) was utilized to determine the relative expression levels of the identified genes | ||
| 520 | |a RESULTS: No mutations were observed in the whole FKS1 gene hot spot regions of the FKS1 genes in the resistant isolates. A subset of two genes with known biological functions and four genes with unknown biological functions were identified in the CAS-resistant isolates using the CDNA-AFLP. The QRT-PCR revealed the down-regulation of the P-type ATPase and ubiquinone biosynthesis methyltransferase COQ5 in the CAS-resistant isolates, compared to the susceptible isolates | ||
| 520 | |a CONCLUSION: The findings showed that P-type ATPase and ubiquinone biosynthesis methyltransferase COQ5 might be involved in the CAS-resistance A. flavus clinical isolates. Moreover, a subset of genes was differentially expressed to enhance fungi survival in CAS exposure. Further studies are recommended to highlight the gene overexpression and knock-out experiments in A. flavus or surrogate organisms to confirm that these mentioned genes confer the CAS resistant A. flavus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aspergillus flavus | |
| 650 | 4 | |a CDNA-AFLP | |
| 650 | 4 | |a Caspofungin resistance | |
| 650 | 4 | |a P-type ATPase | |
| 650 | 4 | |a Ubiquinone biosynthesis methyltransferase COQ5 | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Echinocandins |2 NLM | |
| 650 | 7 | |a Caspofungin |2 NLM | |
| 650 | 7 | |a F0XDI6ZL63 |2 NLM | |
| 700 | 1 | |a Lotfali, Ensieh |e verfasserin |4 aut | |
| 700 | 1 | |a Khourgami, Mohammad Rafi |e verfasserin |4 aut | |
| 700 | 1 | |a Omidi, Negar |e verfasserin |4 aut | |
| 700 | 1 | |a Fattahi, Azam |e verfasserin |4 aut | |
| 700 | 1 | |a Nasrollahi, Saman Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemi, Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal de mycologie medicale |d 1997 |g 31(2021), 4 vom: 17. Dez., Seite 101166 |w (DE-627)NLM093691998 |x 1773-0449 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:4 |g day:17 |g month:12 |g pages:101166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.mycmed.2021.101166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 4 |b 17 |c 12 |h 101166 | ||